PBM FAIR Act
- Bill Number
- S. 3549
- Origin Chamber
- Senate
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-12-17: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- Last Updated
- 2026-01-26T13:57:50Z
AI-Generated Summary
Purpose of the Legislation
The PBM FAIR Act aims to increase accountability for pharmacy benefit managers (PBMs)—companies that manage prescription drug benefits for health plans—by classifying them as fiduciaries under the Employee Retirement Income Security Act of 1974 (ERISA). This ensures they act in the best interests of employee health plans, focusing on fair handling of drug pricing, networks, and claims.
Key Provisions
- Fiduciary Status for PBMs: PBMs are automatically considered fiduciaries for group health plans if they:
- Maintain prescription drug networks or formularies (lists of covered drugs) through purchases from manufacturers, distributors, or other parties.
- Negotiate rebates, fees, discounts, or other price concessions for drugs.
- Process and pay drug claims.
- Conduct utilization reviews (evaluations of medical necessity) for drugs.
- Compensation Disclosures: PBMs and third-party administrators must disclose all direct and indirect compensation (e.g., fees or rebates) related to drug services, including network maintenance and claims processing. This applies to services for covered plans.
- Limits on Fiduciary Roles: Service providers like PBMs cannot act as the "responsible plan fiduciary" for their own disclosure requirements, except when a PBM sponsors its own employee plan.
- Ban on Indemnification: PBMs deemed fiduciaries cannot be protected (indemnified) from liability for breaching their duties, and any contract provision allowing this is void as against public policy.
- Effective Date: Changes apply to plan years starting at least 12 months after the bill's enactment.
Significant Changes to Existing Law
- Expands Fiduciary Definition: ERISA's Section 3(21) is amended to explicitly include PBM activities, which were not previously covered, making PBMs directly accountable for acting solely in the plan's interest (e.g., avoiding self-dealing).
- Enhances Disclosure Rules: Updates ERISA's Section 408(b)(2) to require detailed reporting of PBM and third-party compensation, building on existing rules for service providers but targeting drug-related services specifically.
- Strengthens Enforcement: Adds prohibitions on indemnification in ERISA's Section 410, closing loopholes that allowed PBMs to shift liability, and includes a technical fix for clarity in disclosure language.
These changes promote transparency and fiduciary responsibility without altering core ERISA structures for other plan aspects.
Potential Impacts
- On Government Agencies: The Department of Labor (which oversees ERISA) may see increased enforcement duties, such as reviewing disclosures and investigating breaches, potentially requiring more resources for compliance monitoring.
- On Citizens: Employees and beneficiaries in employer-sponsored health plans could benefit from fairer drug pricing and reduced conflicts of interest, possibly leading to lower out-of-pocket costs or better access to medications, though short-term adjustments might affect plan premiums.
- On International Relations: Minimal direct impact, as the bill focuses on domestic employee benefits; however, it could indirectly influence U.S. drug manufacturers' global rebate negotiations if PBM practices change.
Main Stakeholders Affected
- Pharmacy Benefit Managers (PBMs): Face new fiduciary duties, disclosure mandates, and liability risks, requiring operational changes to comply.
- Group Health Plans and Sponsors: Employers offering health coverage gain tools for oversight but must review contracts and disclosures.
- Plan Administrators and Health Insurers: Impacted by requirements for claims processing and utilization management; insurers offering group coverage must ensure PBM partners meet standards.
- Employees and Beneficiaries: Indirectly affected through potential improvements in drug benefit fairness and cost control.
- Drug Manufacturers, Distributors, and Wholesalers: May experience shifts in rebate and pricing negotiations due to increased PBM accountability.
Notable Legal, Constitutional, or Political Implications
- Legal Implications: Reinforces ERISA's fiduciary standards (requiring loyalty and prudence), potentially increasing litigation over PBM breaches, such as improper rebate handling. Courts may interpret the new deeming provision broadly, affecting contract enforceability.
- Constitutional Implications: Aligns with Congress's authority to regulate interstate commerce and employee benefits; no apparent conflicts with free speech or due process, as it targets commercial practices.
- Political Implications: Bipartisan support (introduced by Sens. Marshall, Kaine, Grassley, and Hassan) signals focus on healthcare transparency amid concerns over drug costs. Could set precedent for regulating other intermediaries in benefits, influencing future reforms without major partisan divides evident in the text.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (3)
Sen. Kaine, Tim [D-VA], Sen. Grassley, Chuck [R-IA], Sen. Hassan, Margaret Wood [D-NH]
Recent Actions
- 2025-12-17: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
- 2025-12-17: Introduced in Senate
Bill Versions
- PBM Fiduciary Accountability, Integrity, and Reform (FAIR) Act — issued 2025-12-17 — PDF (5 pages)